鹿得医疗(832278) - 2025 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2025 was CNY 61,093,741.90, a decrease of 7.42% from CNY 65,987,957.04 in Q1 2024[8] - Net profit attributable to shareholders rose by 62.89% to CNY 6,334,320.18, up from CNY 3,888,729.21 in the same period last year[8] - The company reported a profit before tax of CNY 7,017,203.39, a 71.90% increase compared to the previous year[10] - Net profit for Q1 2025 reached CNY 6,277,910.07, an increase of 61.4% from CNY 3,888,729.21 in Q1 2024[35] - Operating profit reached 8,290,488.11, up from 4,585,361.65, reflecting an increase of 80.5%[39] Cash Flow - The net cash flow from operating activities surged by 382.92% to CNY 64,091,884.56, compared to a negative cash flow of CNY 22,653,367.65 in Q1 2024[8][10] - The net cash flow from operating activities for Q1 2025 was ¥58,886,641.34, a significant improvement compared to a net outflow of ¥23,013,106.94 in Q1 2024[42] - Total cash inflow from operating activities in Q1 2025 reached ¥133,072,547.55, compared to ¥56,824,117.73 in Q1 2024, indicating a year-over-year increase of approximately 134%[42] - The net cash flow from investing activities in Q1 2025 was -¥4,696,670.50, a decline from a positive net cash flow of ¥8,648,717.30 in Q1 2024[42] - The net cash flow from financing activities for Q1 2025 was ¥23,876,263.55, compared to ¥9,849,899.17 in Q1 2024, showing an increase of approximately 142%[43] Assets and Liabilities - Total assets increased by 5.70% to CNY 559,732,344.84 as of March 31, 2025, compared to CNY 529,562,627.45 at the end of 2024[8] - The company’s total liabilities to assets ratio increased to 27.37% from 24.43% year-on-year[8] - Total liabilities increased to CNY 153,253,930.88 as of March 31, 2025, compared to CNY 129,362,123.56 on December 31, 2024, reflecting an increase of approximately 18.5%[30] - Short-term borrowings rose significantly by 163.90% to CNY 54,929,101.36, reflecting new bank credit loans[9] - Total current assets increased to CNY 363,563,227.26 as of March 31, 2025, up from CNY 333,195,217.12 on December 31, 2024, representing an increase of approximately 9.1%[28] Shareholder Information - Total outstanding shares amount to 176,000,000, with 42.92% being unrestricted shares[14] - The top ten shareholders collectively hold 70.40% of the shares, with the largest shareholder owning 22.23%[15] - The company has no pledged or judicially frozen shares among its major shareholders[17] - The number of shareholders holding more than 5% of shares is significant, with the largest individual shareholder being a natural person[15] Other Financial Metrics - The weighted average return on equity based on net profit attributable to shareholders increased to 1.57% from 0.99% year-on-year[8] - Basic earnings per share for Q1 2025 were CNY 0.04, compared to CNY 0.02 in Q1 2024, representing a 100% increase[35] - Non-recurring gains and losses totaled CNY 81,089.98 after tax, reflecting the impact of government subsidies and other factors[12] - The company reported a credit impairment loss of CNY 2,877,616.57 in Q1 2025, compared to a gain of CNY 643,990.01 in Q1 2024[35] Commitments and Legal Matters - The company has disclosed commitments related to stock issuance and price stabilization measures, all of which have been fulfilled by the reporting period[24] - There are no significant litigation or arbitration matters that would adversely affect the company's operations[21] - The company has not engaged in any external guarantees or loans during the reporting period[20] - The company has not undergone any changes in accounting policies or corrections of accounting errors during the reporting period[14]